查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1611255

乾眼症治療市場規模、佔有率、趨勢分析報告：按類型、按藥物、副產品、按劑型、按銷售管道、按分銷管道、按地區、細分市場預測，2025-2030年

Dry Eye Syndrome Treatment Market Size, Share & Trends Analysis Report By Type, By Drug, By Product, By Dosage Form, By Sales Channel, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

乾眼症治療市場成長與趨勢

Grand View Research, Inc.的最新報告顯示，預計2030年全球乾眼症治療市場規模將達92億美元，2025年至2030年複合年成長率為6.5%。

市場成長歸因於螢幕使用量增加、老年人口增加、眼科疾病率上升等因素。

有螢幕設備的使用增加、電腦使用的快速成長以及眨眼次數的減少都導致了蒸發性乾眼症在全球範圍內的成長。例如，根據 2021 年《前沿雜誌》的報道，與大流行之前相比，在 COVID-19 大流行期間，成年人的螢幕使用率增加了 60-80%。接觸螢幕會使眨眼次數減少 66%，從而增加淚液蒸發並導致眼睛乾澀。

由於處方接受率極低，非處方藥（OTC）佔據市場主導地位。例如，只有10%被診斷為乾眼症的患者接受合併治療，75%的患者從未嘗試過合併治療。然而，診斷為乾眼症的患者人數佔所有眼科醫師諮詢的5%至35%。

此外，Zydra 和 Restasis 等現有產品需要數月或數週才能生效。此外，眼科醫師表示這些產品有耐受性問題，失敗率高達 50%。因此，市場上存在未滿足的需求，預計將為未來幾年推出的研發線產品創造利潤豐厚的機會。此外，與製藥相關的法規正在阻礙整體市場的成長。例如，2020年，在監管機構對Xydra的使用提出強烈反對後，諾華被迫自願撤回Xydra在歐洲的使用。

主要企業的創新和策略舉措正在推動市場發展。推出新產品是企業採取的常見策略。例如，2021年10月，Oyster Point Pharma的Tyrvaya（Varenicline溶液）鼻噴霧被FDA核准作為替代治療方法。

乾眼症治療市場報告亮點

  • 按類型分類，蒸發性乾眼症在 2024 年佔據最大的市場佔有率，預計在預測期內將以最快的複合年成長率成長。
  • 從劑型來看，眼藥水/液體佔據市場主導地位，2024年佔有率最大，為64.68%。
  • 以藥品來看，Xiidra 細分市場在整個市場佔據主導地位，2024 年收益佔有率為 8.52%。
  • 按分銷管道分類，由於消費者對網路藥局的便利性越來越偏好，預計線上藥局在預測期內將以最快的速度成長。
  • 由於疾病盛行率高、意識提高和治療率提高，北美在 2023 年佔據市場主導地位。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章乾眼症治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 乾眼症治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章乾眼症治療市場：按類型估計和趨勢分析

  • 細分儀表板
  • 乾眼症治療市場：類型變異分析
  • 乾眼症治療市場：按類型分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 蒸發性乾眼症
  • 淚腺分泌過少的乾眼症

第5章乾眼症治療市場：依藥物估算與趨勢分析

  • 細分儀表板
  • 乾眼症治療市場：藥物波動分析
  • 乾眼症治療市場：按藥物分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 西德拉
  • 恢復
  • 塞誇
  • 蒂亞
  • 艾斯維斯
  • 其他

第6章乾眼症治療市場：依產品估計與趨勢分析

  • 細分儀表板
  • 乾眼症治療市場：產品波動分析
  • 乾眼症治療市場：依產品分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 人工淚液
  • Cyclosporine
  • 局部皮質類固醇
  • 淚點塞
  • 口服歐米茄補充品
  • 其他

第7章乾眼症治療市場：按劑型的估計與趨勢分析

  • 細分儀表板
  • 乾眼症治療市場：劑型變化分析
  • 乾眼症治療市場：按劑型分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 眼藥水/溶液
  • 軟膏和凝膠
  • 膠囊/片劑（補充品）
  • 其他

第8章乾眼症治療市場：依銷售管道估算及趨勢分析

  • 細分儀表板
  • 乾眼症治療市場：銷售管道波動分析
  • 乾眼症治療市場：依銷售管道分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 處方
  • 在商店
  • 其他

第9章乾眼症治療市場：按分銷管道估計和趨勢分析

  • 細分儀表板
  • 乾眼症治療市場：通路波動分析
  • 乾眼症治療市場：按分銷管道分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 零售藥房
  • 醫院藥房
  • 網路藥房

第10章乾眼症治療市場：按地區估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第11章競爭格局

  • 公司分類
  • 主要市場參與企業的最新趨勢和影響分析
  • 2024 年企業市場佔有率分析
  • 公司簡介
    • Novartis AG
    • AbbVie, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Santen Pharmaceutical Co Ltd.
    • AFT Pharmaceuticals
    • Johnson & Johnson Services, Inc.
    • 大塚製藥株式會社（大塚控股株式會社的子公司）
    • OASIS Medical
    • Oyster Point Pharma, Inc.（2023 年 1 月被 Viatris Inc. 收購）
    • Bausch Health Companies, Inc.
Product Code: GVR-4-68039-974-4

Dry Eye Syndrome Treatment Market Growth & Trends:

The global dry eye syndrome treatment market size is estimated to reach USD 9.20 billion by 2030, expanding at a CAGR of 6.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as the increasing use of screens, the rising geriatric population, and a heightened prevalence of eye diseases.

The heightened use of devices with a screen, surging use of computers, and a decreased number of blinks are subsequently leading to the growth of evaporative dry eye syndrome globally. For instance, as per Frontiers Journal in 2021, when compared to pre-pandemic years, the use of screens has increased by 60-80% in adults during the COVID-19 pandemic. The exposure to the screen leads to a 66% decreased blinking rate, thus escalating the evaporation of tears and leading to dry eye disease.

Over-the-counter (OTC) products predominate the marketplace due to the extremely low acceptance of prescription products. For instance, only 10% of the diagnosed population is on prescription therapies, while 75% of the population has never tried prescription therapy. However, the number of patients diagnosed with dry eye syndrome accounts for 5-35% of overall ophthalmologist visits.

Moreover, existing products such as Xiidra and Restasis take months or weeks to demonstrate effects. In addition, as per eye consultants, these products have tolerability issues and a failure rate of as high as 50%. This depicts an unmet need in the market and is anticipated to create a lucrative opportunity for pipeline products expected to launch in the upcoming years. Moreover, regulations associated with the drugs further hamper the growth of the overall market. For instance, in 2020, Novartis had to voluntarily withdraw the use of Xiidra in Europe after regulators raised major objections to its use of xiidra.

Innovations and strategic initiatives by key players are driving the market. New product launch is a common strategy being used by the players. For instance, in October 2021, Tyrvaya (varenicline solution) nasal spray by Oyster Point Pharma was approved by the FDA as an alternative treatment approach.

Dry Eye Syndrome Treatment Market Report Highlights:

  • By type, Evaporative dry eye syndrome segment dominated the market with the largest market share in 2024 and is also anticipated to grow with the fastest CAGR during the forecast period
  • Based on dosage form, The eye drops/ solutions segment dominated the market with the largest share of 64.68% in 2024
  • By drug, The Xiidra segment dominated the overall market in 2024, with a revenue share of 8.52%.
  • Based on distribution channel, online pharmacies are expected to grow at the fastest rate over the forecast period due to the increased consumer preference for online pharmacies owing to the convenience
  • North America dominated the market in 2023 due to the high prevalence of the disease, surging awareness, and enhanced treatment rate

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drugs
    • 1.2.3. Product
    • 1.2.4. Dosage Form
    • 1.2.5. Sales Channel
    • 1.2.6. Distribution Channel
    • 1.2.7. Regional Scope
    • 1.2.8. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Drugs outlook
    • 2.2.3. Product outlook
    • 2.2.4. Dosage form outlook
    • 2.2.5. Sales channel outlook
    • 2.2.6. Distribution channel outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Dry Eye Syndrome Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing geriatric population
      • 3.2.1.2. Increasing prevalence of dry eye syndrome
      • 3.2.1.3. Robust product pipeline
      • 3.2.1.4. Growing disease awareness and increasing use of contact lenses
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Competition from generic products
      • 3.2.2.2. High cost of treatments and lack of awareness among the general population in low- and middle-income countries
  • 3.3. Dry Eye Syndrome Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Dry Eye Syndrome Treatment Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Dry Eye Syndrome Treatment Market: Type Movement Analysis
  • 4.3. Dry Eye Syndrome Treatment Market by Type Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Evaporative Dry Eye Syndrome
    • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.6. Aqueous Deficient Dry Eye Syndrome
    • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Dry Eye Syndrome Treatment Market: Drugs Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Dry Eye Syndrome Treatment Market: Drugs Movement Analysis
  • 5.3. Dry Eye Syndrome Treatment Market by Drugs Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Xiidra
    • 5.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.6. Restasis
    • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.7. Cequa
    • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.8. Tyrvaya
    • 5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.9. Eysuvis
    • 5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.10. Others
    • 5.10.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Dry Eye Syndrome Treatment Market: Product Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Dry Eye Syndrome Treatment Market: Product Movement Analysis
  • 6.3. Dry Eye Syndrome Treatment Market by Product Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Artificial Tears
    • 6.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.6. Cyclosporine
    • 6.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.7. Topical Corticosteroids
    • 6.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.8. Punctal Plugs
    • 6.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.9. Oral Omega Supplements
    • 6.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7. Dry Eye Syndrome Treatment Market: Dosage Form Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Dry Eye Syndrome Treatment Market: Dosage Form Movement Analysis
  • 7.3. Dry Eye Syndrome Treatment Market by Dosage Form Outlook (USD Million)
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Eye Drops/ Solutions
    • 7.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.6. Ointments and Gels
    • 7.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.7. Capsules & Tablets (For Supplements)
    • 7.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.8. Other Dosage Forms
    • 7.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8. Dry Eye Syndrome Treatment Market: Sales Channel Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Dry Eye Syndrome Treatment Market: Sales Channel Movement Analysis
  • 8.3. Dry Eye Syndrome Treatment Market by Sales Channel Outlook (USD Million)
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.5. Prescription
    • 8.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.6. OTC
    • 8.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.7. Others
    • 8.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9. Dry Eye Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Dry Eye Syndrome Treatment Market: Distribution Channel Movement Analysis
  • 9.3. Dry Eye Syndrome Treatment Market by Distribution Channel Outlook (USD Million)
  • 9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 9.5. Retail Pharmacies
    • 9.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.6. Hospital Pharmacies
    • 9.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.7. Online Pharmacies
    • 9.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 10. Dry Eye Syndrome Treatment Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Dashboard
  • 10.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 10.3. North America
    • 10.3.1. U.S.
      • 10.3.1.1. Key country dynamics
      • 10.3.1.2. Regulatory framework/ reimbursement structure
      • 10.3.1.3. Competitive scenario
      • 10.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.2. Canada
      • 10.3.2.1. Key country dynamics
      • 10.3.2.2. Regulatory framework/ reimbursement structure
      • 10.3.2.3. Competitive scenario
      • 10.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.3. Mexico
      • 10.3.3.1. Key country dynamics
      • 10.3.3.2. Regulatory framework/ reimbursement structure
      • 10.3.3.3. Competitive scenario
      • 10.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4. Europe
    • 10.4.1. UK
      • 10.4.1.1. Key country dynamics
      • 10.4.1.2. Regulatory framework/ reimbursement structure
      • 10.4.1.3. Competitive scenario
      • 10.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.2. Germany
      • 10.4.2.1. Key country dynamics
      • 10.4.2.2. Regulatory framework/ reimbursement structure
      • 10.4.2.3. Competitive scenario
      • 10.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.3. France
      • 10.4.3.1. Key country dynamics
      • 10.4.3.2. Regulatory framework/ reimbursement structure
      • 10.4.3.3. Competitive scenario
      • 10.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.4. Italy
      • 10.4.4.1. Key country dynamics
      • 10.4.4.2. Regulatory framework/ reimbursement structure
      • 10.4.4.3. Competitive scenario
      • 10.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.5. Spain
      • 10.4.5.1. Key country dynamics
      • 10.4.5.2. Regulatory framework/ reimbursement structure
      • 10.4.5.3. Competitive scenario
      • 10.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.6. Norway
      • 10.4.6.1. Key country dynamics
      • 10.4.6.2. Regulatory framework/ reimbursement structure
      • 10.4.6.3. Competitive scenario
      • 10.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.7. Sweden
      • 10.4.7.1. Key country dynamics
      • 10.4.7.2. Regulatory framework/ reimbursement structure
      • 10.4.7.3. Competitive scenario
      • 10.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.8. Denmark
      • 10.4.8.1. Key country dynamics
      • 10.4.8.2. Regulatory framework/ reimbursement structure
      • 10.4.8.3. Competitive scenario
      • 10.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5. Asia Pacific
    • 10.5.1. Japan
      • 10.5.1.1. Key country dynamics
      • 10.5.1.2. Regulatory framework/ reimbursement structure
      • 10.5.1.3. Competitive scenario
      • 10.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.2. China
      • 10.5.2.1. Key country dynamics
      • 10.5.2.2. Regulatory framework/ reimbursement structure
      • 10.5.2.3. Competitive scenario
      • 10.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.3. India
      • 10.5.3.1. Key country dynamics
      • 10.5.3.2. Regulatory framework/ reimbursement structure
      • 10.5.3.3. Competitive scenario
      • 10.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.4. Australia
      • 10.5.4.1. Key country dynamics
      • 10.5.4.2. Regulatory framework/ reimbursement structure
      • 10.5.4.3. Competitive scenario
      • 10.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.5. South Korea
      • 10.5.5.1. Key country dynamics
      • 10.5.5.2. Regulatory framework/ reimbursement structure
      • 10.5.5.3. Competitive scenario
      • 10.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.6. Thailand
      • 10.5.6.1. Key country dynamics
      • 10.5.6.2. Regulatory framework/ reimbursement structure
      • 10.5.6.3. Competitive scenario
      • 10.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6. Latin America
    • 10.6.1. Brazil
      • 10.6.1.1. Key country dynamics
      • 10.6.1.2. Regulatory framework/ reimbursement structure
      • 10.6.1.3. Competitive scenario
      • 10.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.2. Argentina
      • 10.6.2.1. Key country dynamics
      • 10.6.2.2. Regulatory framework/ reimbursement structure
      • 10.6.2.3. Competitive scenario
      • 10.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7. MEA
    • 10.7.1. South Africa
      • 10.7.1.1. Key country dynamics
      • 10.7.1.2. Regulatory framework/ reimbursement structure
      • 10.7.1.3. Competitive scenario
      • 10.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.2. Saudi Arabia
      • 10.7.2.1. Key country dynamics
      • 10.7.2.2. Regulatory framework/ reimbursement structure
      • 10.7.2.3. Competitive scenario
      • 10.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.3. UAE
      • 10.7.3.1. Key country dynamics
      • 10.7.3.2. Regulatory framework/ reimbursement structure
      • 10.7.3.3. Competitive scenario
      • 10.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.4. Kuwait
      • 10.7.4.1. Key country dynamics
      • 10.7.4.2. Regulatory framework/ reimbursement structure
      • 10.7.4.3. Competitive scenario
      • 10.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Company Categorization
  • 11.2. Recent Developments & Impact Analysis by Key Market Participants
  • 11.3. Company Market Share Analysis, 2024
  • 11.4. Company overview
    • 11.4.1. Novartis AG
      • 11.4.1.1. Company Overview
      • 11.4.1.2. Financial performance
      • 11.4.1.3. Product benchmarking
      • 11.4.1.4. Strategic initiatives
    • 11.4.2. AbbVie, Inc.
      • 11.4.2.1. Company Overview
      • 11.4.2.2. Financial performance
      • 11.4.2.3. Product benchmarking
      • 11.4.2.4. Strategic initiatives
    • 11.4.3. Sun Pharmaceutical Industries Ltd.
      • 11.4.3.1. Company Overview
      • 11.4.3.2. Financial performance
      • 11.4.3.3. Product benchmarking
      • 11.4.3.4. Strategic initiatives
    • 11.4.4. Santen Pharmaceutical Co Ltd.
      • 11.4.4.1. Company Overview
      • 11.4.4.2. Financial performance
      • 11.4.4.3. Product benchmarking
      • 11.4.4.4. Strategic initiatives
    • 11.4.5. AFT Pharmaceuticals
      • 11.4.5.1. Company Overview
      • 11.4.5.2. Financial performance
      • 11.4.5.3. Product benchmarking
      • 11.4.5.4. Strategic initiatives
    • 11.4.6. Johnson & Johnson Services, Inc.
      • 11.4.6.1. Company Overview
      • 11.4.6.2. Financial performance
      • 11.4.6.3. Product benchmarking
      • 11.4.6.4. Strategic initiatives
    • 11.4.7. Otsuka Pharmaceutical Co., Ltd. (subsidiary of Otsuka Holdings Co., Ltd.)
      • 11.4.7.1. Company Overview
      • 11.4.7.2. Financial performance
      • 11.4.7.3. Product benchmarking
      • 11.4.7.4. Strategic initiatives
    • 11.4.8. OASIS Medical
      • 11.4.8.1. Company Overview
      • 11.4.8.2. Financial performance
      • 11.4.8.3. Product benchmarking
      • 11.4.8.4. Strategic initiatives
    • 11.4.9. Oyster Point Pharma, Inc. (acquired by Viatris Inc. in January 2023)
      • 11.4.9.1. Company Overview
      • 11.4.9.2. Financial performance
      • 11.4.9.3. Product benchmarking
      • 11.4.9.4. Strategic initiatives
    • 11.4.10. Bausch Health Companies, Inc.
      • 11.4.10.1. Company Overview
      • 11.4.10.2. Financial performance
      • 11.4.10.3. Product benchmarking
      • 11.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 4 Global dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 5 Global dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 6 Global dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 7 Global dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 8 Global dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 9 North America dry eye syndrome treatment, by country, 2018 - 2030 (USD Billion)
  • Table 10 North America dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 11 North America dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 12 North America dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 13 North America dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 14 North America dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 15 North America dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 16 U.S. dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 17 U.S. dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 18 U.S. dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 19 U.S. dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 20 U.S. dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 21 U.S. dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 22 Canada dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 23 Canada dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 24 Canada dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 25 Canada dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 26 Canada dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 27 Canada dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 28 Mexico dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 29 Mexico dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 30 Mexico dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 31 Mexico dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 32 Mexico dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 33 Mexico dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 34 Europe dry eye syndrome treatment, by country, 2018 - 2030 (USD Billion)
  • Table 35 Europe dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 36 Europe dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 37 Europe dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 38 Europe dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 39 Europe dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 40 Europe dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 41 UK dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 42 UK dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 43 UK dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 44 UK dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 45 UK dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 46 UK dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 47 Germany dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 48 Germany dry eye syndrome treatment, by drugs 2018 - 2030 (USD Billion)
  • Table 49 Germany dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 50 Germany dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 51 Germany dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 52 Germany dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 53 France dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 54 France dry eye syndrome treatment, by drugs 2018 - 2030 (USD Billion)
  • Table 55 France dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 56 France dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 57 France dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 58 France dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 59 Italy dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 60 Italy dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 61 Italy dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 62 Italy dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 63 Italy dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 64 Italy dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 65 Spain dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 66 Spain dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 67 Spain dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 68 Spain dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 69 Spain dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 70 Spain dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 71 Denmark dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 72 Denmark dry eye syndrome treatment, by drugs 2018 - 2030 (USD Billion)
  • Table 73 Denmark dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 74 Denmark dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 75 Denmark dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 76 Denmark dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 77 Norway dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 78 Norway dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 79 Norway dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 80 Norway dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 81 Norway dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 82 Norway dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 83 Sweden dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 84 Sweden dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 85 Sweden dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 86 Sweden dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 87 Sweden dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 88 Sweden dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 89 Asia Pacific dry eye syndrome treatment, by country, 2018 - 2030 (USD Billion)
  • Table 90 Asia Pacific dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 91 Asia Pacific dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 92 Asia Pacific dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 93 Asia Pacific dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 94 Asia Pacific dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 95 Asia Pacific dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 96 Japan dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 97 Japan dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 98 Japan dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 99 Japan dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 100 Japan dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 101 Japan dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 102 China dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 103 China dry eye syndrome treatment, by drugs 2018 - 2030 (USD Billion)
  • Table 104 China dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 105 China dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 106 China dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 107 China dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 108 India dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 109 India dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 110 India dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 111 India dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 112 India dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 113 India dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 114 Australia dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 115 Australia dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 116 Australia dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 117 Australia dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 118 Australia dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 119 Australia dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 120 South Korea dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 121 South Korea dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 122 South Korea dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 123 South Korea dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 124 South Korea dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 125 South Korea dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 126 Thailand dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 127 Thailand dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 128 Thailand dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 129 Thailand dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 130 Thailand dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 131 Thailand dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 132 Latin America dry eye syndrome treatment, by country, 2018 - 2030 (USD Billion)
  • Table 133 Latin America dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 134 Latin America dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 135 Latin America dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 136 Latin America dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 137 Latin America dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 138 Latin America dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 139 Latin America dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 140 Brazil dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 141 Brazil dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 142 Brazil dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 143 Brazil dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 144 Brazil dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 145 Brazil dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 146 Brazil dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 147 Argentina dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 148 Argentina dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 149 Argentina dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 150 Argentina dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 151 Argentina dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 152 Argentina dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 153 Argentina dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 154 Middle East & Africa dry eye syndrome treatment, by country, 2018 - 2030 (USD Billion)
  • Table 155 Middle East & Africa dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 156 Middle East & Africa dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 157 Middle East & Africa dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 158 Middle East & Africa dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 159 Middle East & Africa dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 160 Middle East & Africa dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 161 Middle East & Africa dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 162 South Africa dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 163 South Africa dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 164 South Africa dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 165 South Africa dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 166 South Africa dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 167 South Africa dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 168 South Africa dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 169 Saudi Arabia dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 170 Saudi Arabia dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 171 Saudi Arabia dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 172 Saudi Arabia dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 173 Saudi Arabia dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 174 Saudi Arabia dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 175 Saudi Arabia dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 176 UAE dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 177 UAE dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 178 UAE dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 179 UAE dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 180 UAE dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 181 UAE dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 182 UAE dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 183 Kuwait dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 184 Kuwait dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 185 Kuwait dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 186 Kuwait dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 187 Kuwait dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 188 Kuwait dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 189 Kuwait dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Dry eye syndrome treatment market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Dry eye syndrome treatment market: Type outlook and key takeaways
  • Fig. 12 Dry eye syndrome treatment market: Type movement analysis
  • Fig. 13 Evaporative dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Aqueous deficient dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Dry eye syndrome treatment market: Drugs outlook and key takeaways
  • Fig. 16 Dry eye syndrome treatment market: Drugs movement analysis
  • Fig. 17 Xiidra dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Restasis dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Cequa dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Tyrvaya dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Eysuvis dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Dry eye syndrome treatment market: Dosage form outlook and key takeaways
  • Fig. 24 Dry eye syndrome treatment market: Dosage form movement analysis
  • Fig. 25 Eye drops/ solutions dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Ointments and gels dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Capsules & tablets (for supplements) dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Other dosage forms dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Dry eye syndrome treatment market: Sales channel outlook and key takeaways
  • Fig. 30 Dry eye syndrome treatment market: Sales channel movement analysis
  • Fig. 31 Prescription dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 OTC dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Others dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Dry eye syndrome treatment market: Distribution channel outlook and key takeaways
  • Fig. 35 Dry eye syndrome treatment market: Distribution channel movement analysis
  • Fig. 36 Retail Pharmacies dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Hospital Pharmacies dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Online Pharmacies dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Dry Eye Syndrome Treatment Market: Regional outlook and key takeaways
  • Fig. 40 Dry eye syndrome treatment: Regional movement analysis
  • Fig. 41 Dry eye disease syndrome market: regional key takeaways (USD Billion)
  • Fig. 42 Dry eye disease syndrome market: regional outlook, 2024 & 2030, USD Billion
  • Fig. 43 North America dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 U.S. dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 Canada dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 46 Mexico dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 47 Europe dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 48 UK dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 49 Germany dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 50 France dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 51 Spain dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 52 Italy dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 53 Norway dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 54 Denmark dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 55 Sweden dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 56 Asia Pacific dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 57 China dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 58 Japan dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 59 India dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 60 South Korea dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 61 Australia dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 62 Thailand dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 63 Latin America dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 64 Brazil dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 65 Argentina dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 66 Middle East and Africa dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 67 South Africa dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 68 Saudi Arabia dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 69 UAE dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 70 Kuwait dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 71 List of key emerging company's/technology disruptors/innovators